In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
US Pharma and Biotech Summit 2024: Evolving clinical research
In this news article, Applied Clinical Trials reports on ICON CEO Steve Cutler’s discussion at the FT US Pharma and Biotech Summit. Topics addressed included the evolution of the CRO and sponsor relationship, the potential of AI in the clinical development space, and how ICON is helping customers build strong portfolios.
-
Overcoming Challenges in the Development of Antibody Drug Conjugates
In this article, ICON’s Andreas Dreps reviews the innovations that have helped ADCs overcome clinical development challenges.
-
Toward more intelligent collaboration: implementing data in partnerships
In this article from Pharmaceutical Outsourcing, Debbie Gilmore, Vice President, Strategic Alliance Management, Ruth Lalor, Vice President, Business Operations and Robert Ellison, Vice President, Data & Applied Analytics, outline how data can play a key role in supporting collaboration and achieving objectives, as strategic partnerships become more important in clinical research outsourcing models.
-
Taking Stock of Obesity Drug Development: Trends and challenges facing today’s researchers
In this article, CON’s Jack Martin discusses the direction obesity drug research is heading, and the challenges faced by researchers.
-
Say Hello to Flexible: Reimagining the Patient Journey
In this article, Adam Halbridge Clinical Trial Tokenisation Lead and Executive Director, describes how flexibility is reimagining the patient journey and rebalancing the workload for each stakeholder involved.
-
Embedded and agile – The next phase of the DCT evolution
In this article, Darlene Ellenor Director of Project Operations, Decentralized Clinical Trials Operations highlights how DCTs are now considered a patient centric model for sponsors that want to enhance the patient and site experience and generate more robust data. As DCT evolves, an embedded approach backed by the right processes and tools will maximize the benefits that DCTs bring to clinical research.
-
Engineering CAR T-cell sharpshooters
In this article, ICON's Brian Huber explains why and discusses the prospects for the next-generation of CAR T-cell therapies engineered to be more adaptable, precise and controlled.
-
What’s APAC’s recipe of success in clinical trials market?
Suhail Ali, Vice President, Clinical Operations contributes to this piece in BioSpectrum Asia on the thriving clinical research landscape in the APAC region and the trends driving its growth.
-
.jpg?w=545&itok=LNX2K8KX "EPR in healthcare news.")
Application of NGS to enhance the molecular monitoring of CML patients
This Q&A with Dr Jin Li and Dr Chad Galderisi of ICON Specialty Laboratory Solutions discusses ICON’s development of its RNA-based next generation sequencing (NGS) assay that detects mutations in chronic myeloid leukemia (CML) and how it can benefit both routine clinics and clinical trial settings.
-
Advancing Research and Development of Multi-indication and Combination Therapies for Obesity
In this article, ICON's Jack Martin explores the impact of comorbidities on obesity therapeutic development including strategic and innovative approaches to therapeutic development and clinical trials design.
.jpg?w=340&itok=jIOHKQJJ "EPR in healthcare news."){kind=icon}
